KRAS and pancreatic neoplasm: A phase I clinical trial (NCT03948763) of the KRAS mRNA vaccine V941 (mRNA-5671) in KRAS-mutated NSCLC, pancreatic cancer, and CRC has been completed, but no results have been posted.